Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy
Start here
A multiomic analysis of patients with newly diagnosed multiple myeloma treated with isatuximab, carfilzomib, lenalidomide and dexamethasone induction, followed by MRD-status-guided consolidation, found that baseline genomic, transcriptomic and epigenetic features were associated with post-induction MRD status. doi: 10.1038/s41591-026-04692-0.
Excerpted from Nature
Coverage timeline
Follow the coverage to see the different angles.
- NaturePickMolecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy
A multiomic analysis of patients with newly diagnosed multiple myeloma treated with isatuximab, carfilzomib, lenalidomide and dexamethasone induction, followed by MRD-status-guided consolidation, found that baseline genomic, transcriptomic and epigenetic features were associated with post-induction MRD status. doi: 10.1038/s41591-026-04692-0.
Coverage and heat for this story
Reports so far 1·Heat now 7·Peak heat 10 (Oct 19 08:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.